Clinical Trial Update: Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for glofitamab in relapsed or refractory diffuse large B-cell lymphoma after CD19 CAR-T therapy; the study is active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING